Citius Oncology, INC Form 4 insider transactions

A Citius Oncology director reported the acquisition of 21,228 common shares and 250,000 stock options, reflecting changes in beneficial ownership.

Director Joel David Mayersohn of Citius Oncology, Inc. was granted 250,000 stock options on December 12, 2024.

A Citius Oncology director, Eugene Myron Holuka, was granted stock options on December 12, 2024.

Myron Holubiak, a director and officer of Citius Oncology, was granted stock options on December 12, 2024.

A Citius Oncology director, Robert Joseph Smith, was granted 125,000 stock options on December 12, 2024, which will vest after one year of continuous service.

Director Carol Webb of Citius Oncology, Inc. was granted stock options on December 12, 2024, according to a recent SEC Form 4 filing.

Director Suren G. Dutia of Citius Oncology, Inc. was granted stock options on December 12, 2024.

Director Dennis M. McGrath acquired 125,000 stock options in Citius Oncology, Inc. on December 12, 2024.

Citius Oncology's Chief Financial Officer, Jaime Bartushak, was granted 400,000 stock options at an exercise price of $1.07, vesting over three years.

Citius Oncology's CEO, Leonard L. Mazur, was granted stock options on December 12, 2024, as part of his compensation.

Citius Oncology's Chief Medical Officer, Myron Czuczman, was granted 400,000 stock options at an exercise price of $1.07, and holds 1,400,000 options at an exercise price of $2.15.

Citius Oncology's CEO, Leonard Mazur, received 3,700,000 stock options as part of a merger transaction, according to a Form 4/A filing.

Myron Z. Holubiak, a director at Citius Oncology, filed an amended Form 4 to correct the reported amount of stock options held following a merger transaction.

Myron Czuczman, Chief Medical Officer of Citius Oncology, files an amended Form 4 to correct the reported amount of stock options held following a merger transaction.

Jaime Bartushak, CFO of Citius Oncology, reports the acquisition of 1,400,000 stock options following the merger with Citius Oncology Sub, Inc.

Eugene Myron Holuka, a director of Citius Oncology, Inc., acquired stock options for 150,000 shares on August 12, 2024.

Suren G. Dutia, a director of Citius Oncology, Inc., was granted stock options and filed a power of attorney related to SEC filings.

Myron Z. Holubiak, a director of Citius Oncology, Inc., was granted stock options and filed a power of attorney authorizing specific individuals to act on his behalf for SEC filings.

Myron Czuczman, Chief Medical Officer of Citius Oncology, Inc., was granted stock options to purchase 466,667 shares of common stock.

Leonard L. Mazur, CEO of Citius Oncology, Inc., was granted stock options and has filed a Form 4 and Power of Attorney related to changes in beneficial ownership following the merger with Citius Oncology Sub, Inc.

Jaime Bartushak, CFO of Citius Oncology, received stock options and granted power of attorney for SEC filings.

Dennis M. McGrath, a director at Citius Oncology, Inc., was granted stock options and filed a power of attorney, according to recent SEC filings.

Citius Oncology files a Form 4 and Power of Attorney with the SEC, detailing changes in beneficial ownership and designating attorneys-in-fact for regulatory filings.

Director Carol Webb received stock options and filed a power of attorney related to Citius Oncology, Inc.

TenX Keane Acquisition receives a $66,667 deposit from Citius Pharma, extending the deadline for their business combination to August 18, 2024.

TenX Keane Acquisition receives a third one-month extension for its business combination with Citius Pharmaceuticals via a $66,667 deposit.

TenX Keane Acquisition made additional payments to shareholders who redeemed their shares, correcting a miscalculation in the initial redemption price.

TenX Keane Acquisition secures a one-month extension for its business combination deadline through a $66,667 contribution from Citius Pharmaceuticals, evidenced by a promissory note.